Champions Oncology
CSBR
28 hedge funds and large institutions have $37M invested in Champions Oncology in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 2 closing their positions.
57% more capital invested
Capital invested by funds: $23.6M → $37M (+$13.5M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.37% less ownership
Funds ownership: 43.22% → 42.85% (-0.37%)
7% less funds holding
Funds holding: 30 → 28 (-2)
11% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 9
92% less call options, than puts
Call options by funds: $158K | Put options by funds: $2.03M
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$43.7K |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
+$20.9K |
| 3 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
+$19K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$15.1K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$13K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
-$148K |
| 2 |
Millennium Management
New York
|
-$79.6K |
| 3 |
ISL
Ingalls & Snyder LLC
New York
|
-$44K |
| 4 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$26.7K |
| 5 |
Stifel Financial
St. Louis,
Missouri
|
-$21.9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| $287 | +$10 | +2 | +5% |
|
27
JP Morgan Chase
New York
| $69 | – | – | – |
|
|
TRCT
28
Tower Research Capital (TRC)
New York
| $38 | -$13.7K | -2,651 | -100% |
|
|
ISL
29
Ingalls & Snyder LLC
New York
| – | -$44K | -11,056 | Closed |
|
|
SFG
30
Steward Financial Group
Colleyville,
Texas
| – | -$3K | -775 | Closed |
|
CSBR Hedge Fund Activity: Q2 2023 in Review
28 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Champions Oncology (CSBR) for Q2 2023, worth a combined $37M — up 57% from $23.6M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of CSBR and 0 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 8 added.
The largest buyer was Geode Capital Management, adding an estimated $43.7K. The largest seller was Dimensional Fund Advisors, cutting an estimated $148K.
- 28 institutional investors held Champions Oncology (CSBR) as of Q2 2023, down from 30 in Q1 2023.
- Funds reported $37M of Champions Oncology stock for Q2 2023, up 57% quarter-over-quarter.
- 0 funds opened new Champions Oncology positions in Q2 2023 and 2 closed out, a net change of -2 holders.
- The largest Champions Oncology buyer in Q2 2023 was Geode Capital Management, an estimated $43.7K added.
- The largest Champions Oncology seller in Q2 2023 was Dimensional Fund Advisors, an estimated $148K sold.
Based on aggregated 13F filings for Q2 2023.